Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis.
about
Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantationHepatitis C Virus and Liver Transplantation.Recurrent hepatitis C after liver transplantSevere Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.Histopathological evaluation of recurrent hepatitis C after liver transplantation: a reviewIntrahepatic cholestasis in common chronic liver diseases.Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis.Increased hepatic progenitor cell response and ductular reaction in patients with severe recurrent HCV post-liver transplantation.Hepatitis C virus and liver transplantation: where do we stand?Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.Early Acute Severe HCV Recurrence After Transplantation: From Universal Mortality to Cure.Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus-related end-stage liver disease.Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey.Excessive immunosuppression as a potential cause of poor survival in simultaneous liver/kidney transplantation for hepatitis C.Systematic investigation of elevated cholestatic enzymes during the third posttransplant month.Hepatitis C virus-associated cholestatic hepatitis: we cannot seem to agree on diagnostic criteria.
P2860
Q26864478-ECDA3823-D0E4-4B64-9381-5489DED2AB15Q33717116-611BCEE8-66AF-4ABD-8560-A26819890D31Q34067825-F5B03798-22D4-454A-BD59-7CE17CBE6F51Q36190835-5E904BF2-93D2-4EDE-B956-37057D714242Q36760075-8D502456-1040-42E5-82CC-3AF860F43E8BQ36875036-B6691BC0-E537-44D9-A16D-5831E6268E7FQ37654458-0AEE7649-5882-4349-90FF-BA3F2692B478Q38127461-083D683D-9BA7-4884-8CB9-29684D342C45Q38262461-D38B1E4C-BBD8-4A10-B2B4-A1F6D1C613A9Q38381350-DF4DF603-FEE0-4E4E-BBAB-F6A26C41D14DQ38551818-E0DE60FC-FC76-460C-84CD-F0090030FEE0Q38859081-D48CECCD-6140-44CA-9970-BDD74FAD022EQ39007700-DBD8D5F5-128F-4FA4-9DE5-D28CACC5C3CBQ39885523-373AE1FE-063E-4E1B-8226-AE23383369AFQ40162171-7F661787-6997-4DC3-B774-DF9CFD8BB7A2Q40271222-99509F54-5F58-416E-942B-F0A660CEBE7EQ40705940-02E9B3CC-D43D-49C6-B2C8-0F3322B34F84Q41610405-B1299129-8F46-4BF8-8B7B-CCBD9D5D15B0Q41664208-0D4FB5D5-FA9D-4E38-950B-AACECF599741Q42227943-FA72BE4E-2A78-40FF-8E6A-C5BE8D95A527Q42233093-77FB43C1-854F-4C5D-916E-B75C6E6DBFDCQ43572955-3005583F-0192-4004-A687-C047857F2D5EQ44353697-8F235F4A-0510-4004-8708-FF14E7AE0E98
P2860
Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Cholestatic hepatitis C follow ...... cal predictors, and prognosis.
@en
Cholestatic hepatitis C follow ...... cal predictors, and prognosis.
@nl
type
label
Cholestatic hepatitis C follow ...... cal predictors, and prognosis.
@en
Cholestatic hepatitis C follow ...... cal predictors, and prognosis.
@nl
prefLabel
Cholestatic hepatitis C follow ...... cal predictors, and prognosis.
@en
Cholestatic hepatitis C follow ...... cal predictors, and prognosis.
@nl
P2093
P2860
P356
P1476
Cholestatic hepatitis C follow ...... cal predictors, and prognosis.
@en
P2093
Elizabeth C Verna
Jay Lefkowitch
Marcela A Salomao
Rita Abdelmessih
Robert S Brown
Roger K Moreira
P2860
P356
10.1002/LT.23559
P577
2013-01-01T00:00:00Z